Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | KIF18A | Q8NI77 | 8/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648626 | 0.79 | LMNA (0.55) | DRD2AKR1C3 | |
| SCHEMBL12334568 | 0.79 | MBTD1 (0.49) | DRD2AKR1C3KIF18AFFAR4HTR2A | |
| SCHEMBL19707178 | 0.79 | DRD2 (0.47) | DRD2AKR1C3KIF18AFFAR4 | |
| SCHEMBL4015630 | 0.79 | DRD2 (0.50) | DRD2FFAR4HTR2AHTR2CKCNH2 | |
| SCHEMBL4628598 | 0.77 | MBTD1 (0.48) | DRD2AKR1C3KIF18AFFAR4 | |
| SCHEMBL14648627 | 0.77 | LMNA (0.53) | DRD2KIF18A | |
| SCHEMBL777971 | 0.77 | MAPT (0.56) | DRD2AKR1C3HTR2AMAPTMMP8 | |
| SCHEMBL6095946 | 0.75 | DRD2 (0.47) | DRD2AKR1C3FFAR4HTR2AMAPT | |
| SCHEMBL19707128 | 0.75 | DRD2 (0.44) | DRD2AKR1C3KIF18AFFAR4 | |
| SCHEMBL25483288 | 0.75 | MEN1 (0.51) | DRD2FFAR4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442839-B2 | Phenethanolamine derivative for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1556342-B1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20060205794-A1 | Phenethanolamine derivative for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| EP-1556342-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037773-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205794-A1 | Phenethanolamine derivative for the treatment of respiratory diseases | PHOSPHO1, PNMT, NAPEPLD | DRD2 1699/4885AKR1C3 2479/4885KIF18A 1953/4885 |
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | DRD2 254/4885AKR1C3 946/4885KIF18A 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.